Cargando…
Alopecia areata after SARS-CoV-2 vaccination
Autores principales: | Scollan, Margaret E., Breneman, Alyssa, Kinariwalla, Neha, Soliman, Yssra, Youssef, Soundos, Bordone, Lindsey A., Gallitano, Stephanie M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673931/ https://www.ncbi.nlm.nih.gov/pubmed/34931171 http://dx.doi.org/10.1016/j.jdcr.2021.11.023 |
Ejemplares similares
-
Clinical response to oral tofacitinib in pediatric patients with alopecia areata
por: Youssef, Soundos, et al.
Publicado: (2022) -
Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
por: Youssef, Soundos, et al.
Publicado: (2023) -
A case of generalized Sweet syndrome with vasculitis triggered by recent COVID-19 vaccination
por: Kinariwalla, Neha, et al.
Publicado: (2021) -
Two cases of bullous pemphigoid effectively treated with oral tofacitinib
por: Youssef, Soundos, et al.
Publicado: (2022) -
Effective treatment of alopecia universalis with oral upadacitinib
por: Youssef, Soundos, et al.
Publicado: (2022)